Table 1 Demographic and clinical data
Age (years)51 (19–77)
Sex (male/female)29/16
Disease duration (years)5.7 (0.8–28.1)
Acute relapses13/45 (28.9%)
Persistent disease activity in 6 months before enrolment32/45 (71.1%)
No of failed therapies3 (1–10)
Patients with previous cyclophosphamide exposure43 (95.6%)
Cumulative cyclophosphamide dose (g)30.5 (2.5–360)
ANCA positive at entry40/45 (88.9%)
Histological confirmation at diagnosis40 (88.9%)
Renal involvement (at study entry)15 (33.3%)
CRP (mg/dl)9.5 (0–128)
ESR (mm/h)22 (4–103)
BVAS at entry12 (3–25)
VDI at entry4 (0–14)
  • Numerical values are expressed as median and range. ANCA, antineutrophil cytoplasm antibody; BVAS, Birmingham vasculitis activity score; C-ANCA, cytoplasmic staining antineutrophil cytoplasm antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MPO-ANCA, antimyeloperoxidase antibody; PR3-ANCA, antiproteinase 3 antibody; VDI, vasculitis damage index.